Get in touch
Please contact us to discuss how working with Myriad Associates can maximise and secure R&D funding opportunities for your business.
Contact usMyriad Associates is proud to announce that 4 of our clients who applied for the Disruptive Technologies Innovation Fund were all approved on Monday 10th December.
Myriad Associates is proud to announce that 4 of our clients who applied for the Disruptive Technologies Innovation Fund were all approved on Monday 10th December.
With a combined grant value of €14.9m, this will provide a major boost to the MedTech and Cellular Therapy communities in Galway.
The first 27 projects from Ireland’s €500m Disruptive Technologies Innovation Fund (DTIF) were announced this week and will receive a combined €75m in support.
Marc Greatrex, Director of Grants at Myriad Associates commented the success of these applications was a testament to the strength of concepts with the passion, drive and commitment of the SMEs in Galway “We are absolutely thrilled and humbled to have 4 out of 4 applications accepted by the DTIF, we were always hopeful and glad we could help these consortia secure the funding. The technologies they're developing will have a major impact for patients and on the Irish National Strategic Outcomes in the coming years”
The full list of approved projects can be accessed here. They include a scheme to help communities generate their own electricity, new treatments for sepsis, a support system for coastal flooding and advanced 3D printing of medical implants.
Here we offer our 10 top tips for setting up an effective, cohesive R&D department in your company.
Horizon Europe brings big opportunities for innovation in Ireland, boosting the country's competitiveness on a global stage. Find out what it's all about.
The Myriad R&D grants team is proud to have smashed our €100 million funding target. That's definitely something to shout about!
Please contact us to discuss how working with Myriad Associates can maximise and secure R&D funding opportunities for your business.
Contact us